Four insulin manufacturers conspired to deny 340B discounts on their products shipped to contract pharmacies after an effort to lobby the Trump administration failed, a lawsuit alleges.

Insulin Manufacturers Colluded on 340B Contract Pharmacy After Joint Lobbying Push Failed, Lawsuit Alleges

CORRECTION Thursday, Aug. 5, 2021, 8:15 p.m.—Earlier today, we misdescribed Novo Nordisk’s 340B contract pharmacy policy. Beginning on Jan. 1, 2021, Novo Nordisk stopped facilitating bill to/ship to distribution of 340B product to hospital contract pharmacies. We incorrectly said Novo Nordisk later amended its policy to allow 340B contract pharmacies within a 40-mile radius of a hospital. It was Novartis, not Novo Nordisk, that amended its 340B contract pharmacy policy, effective Nov. 16, 2020, to honor hospital contract pharmacy arrangements so long as the contract pharmacy is located within a 40-mile radius of its parent hospital.

UPDATE Thursday, Aug. 5, 2021, 8:15 p.m.—Sanofi late today asked us to update the statement it provided to us yesterday. We have done so. The company says it disagrees with Mosaic Health’s accusations and will vigorously defend itself.

Four insulin manufacturers conspired to cease 340B pricing on drugs shipped to contract pharmacies last year after the failure of a $7 million-plus joint lobbying push to limit 340B discounts for insulin and diabetes medicines, New York health center Mosaic Health alleges in an antitrust class action against the companies.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

*Sign up for news summaries and alerts from 340B Report

Site Footer